Who are Crushed ticagrelor followed by morphine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crushed-ticagrelor-followed-by-morphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Crushed ticagrelor followed by morphine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crushed ticagrelor followed by morphine (Crushed ticagrelor followed by morphine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist + opioid analgesic. Area: Cardiovascular.

marketed P2Y12 receptor antagonist + opioid analgesic P2Y12 receptor (ticagrelor); mu opioid receptor (morphine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Crushed ticagrelor followed by morphine (Crushed ticagrelor followed by morphine) — Collegium Medicum w Bydgoszczy. Crushed ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, followed by morphine administration for pain relief and anxiolysis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Crushed ticagrelor followed by morphine TARGET	Crushed ticagrelor followed by morphine	Collegium Medicum w Bydgoszczy	marketed	P2Y12 receptor antagonist + opioid analgesic	P2Y12 receptor (ticagrelor); mu opioid receptor (morphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist + opioid analgesic class)

Collegium Medicum w Bydgoszczy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Crushed ticagrelor followed by morphine — Competitive Intelligence Brief. https://druglandscape.com/ci/crushed-ticagrelor-followed-by-morphine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab